<DOC>
	<DOC>NCT02611609</DOC>
	<brief_summary>A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The primary hypothesis is that MultiStem will be safe in ARDS patients.</brief_summary>
	<brief_title>A Phase 1/2 Study to Assess MultiStemÂ® Therapy in Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>Diagnosis of moderate to severe ARDS, as defined by the Berlin definition, requiring an endotracheal or tracheal tube Able to receive investigational medicinal product within 96 hours of meeting the last of the ARDS diagnosis criterion Concurrent illness that shortens life expectancy to less than 6 months Other serious medical or psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>